![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
METABOLISM, TRANSPORT, AND PHARMACOGENOMICS
Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Sakyo-ku, Kyoto, Japan
We have examined the role of the human organic cation transporters [hOCTs and human novel organic cation transporter (hOCTN); SLC22A1–5] and apical multidrug and toxin extrusion (hMATE) in the cellular accumulation and cytotoxicity of platinum agents using the human embryonic kidney (HEK) 293 cells transiently transfected with the transporter cDNAs. Both the cytotoxicity and accumulation of cisplatin were enhanced by the expression of hOCT2 and weakly by hOCT1, and those of oxaliplatin were also enhanced by the expression of hOCT2 and weakly by hOCT3. The hOCT-mediated uptake of tetraethylammonium (TEA) was markedly decreased in the presence of cisplatin in a concentration-dependent manner. However, oxaliplatin showed almost no influence on the TEA uptakes in the HEK293 cells expressing hOCT1, hOCT2, and hOCT3. The hMATE1 and hMATE2-K, but not hOCTN1 and OCTN2, mediated the cellular accumulation of cisplatin and oxaliplatin without a marked release of lactate dehydrogenase. Oxaliplatin, but not cisplatin, markedly decreased the hMATE2-K-mediated TEA uptake. However, the inhibitory effect of cisplatin and oxaliplatin against the hMATE1-mediated TEA uptake was similar. The release of lactate dehydrogenase and the cellular accumulation of carboplatin and nedaplatin were not found in the HEK293 cells transiently expressing these seven organic cation transporters. These results indicate that cisplatin is a relatively good substrate of hOCT1, hOCT2, and hMATE1, and oxaliplatin is of hOCT2, hOCT3, hMATE1, and hMATE2-K. These transporters could play predominant roles in the tissue distribution and anticancer effects and/or adverse effects of platinum agent-based chemotherapy.
Address correspondence to: Dr. Ken-ichi Inui, Department of Pharmacy, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan. E-mail: inui{at}kuhp.kyoto-u.ac.jp
This article has been cited by other articles:
|
|
 |
|
  O. Prokopenko and O. Mirochnitchenko Ischemia-reperfusion-inducible protein modulates cell sensitivity to anticancer drugs by regulating activity of efflux transporter Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1086 - C1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Minuesa, C. Volk, M. Molina-Arcas, V. Gorboulev, I. Erkizia, P. Arndt, B. Clotet, M. Pastor-Anglada, H. Koepsell, and J. Martinez-Picado Transport of Lamivudine [(-)-{beta}-L-2',3'-Dideoxy-3'-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3 J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 252 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tsuda, T. Terada, M. Ueba, T. Sato, S. Masuda, T. Katsura, and K.-i. Inui Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Minematsu, M. Iwai, K. Sugimoto, N. Shirai, T. Nakahara, T. Usui, and H. Kamimura Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells Drug Metab. Dispos., March 1, 2009; 37(3): 619 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Shnitsar, R. Eckardt, S. Gupta, J. Grottker, G. A. Muller, H. Koepsell, G. Burckhardt, and Y. Hagos Expression of Human Organic Cation Transporter 3 in Kidney Carcinoma Cell Lines Increases Chemosensitivity to Melphalan, Irinotecan, and Vincristine Cancer Res., February 15, 2009; 69(4): 1494 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yokoo, S. Masuda, A. Yonezawa, T. Terada, T. Katsura, and K.-i. Inui Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal Cancer Drug Metab. Dispos., November 1, 2008; 36(11): 2299 - 2306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okabe, G. Szakacs, M. A. Reimers, T. Suzuki, M. D. Hall, T. Abe, J. N. Weinstein, and M. M. Gottesman Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters Mol. Cancer Ther., September 1, 2008; 7(9): 3081 - 3091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aoki, T. Terada, M. Kajiwara, K. Ogasawara, I. Ikai, O. Ogawa, T. Katsura, and K.-i. Inui Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation Am J Physiol Renal Physiol, July 1, 2008; 295(1): F165 - F170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Filipski, W. J. Loos, J. Verweij, and A. Sparreboom Interaction of Cisplatin with the Human Organic Cation Transporter 2 Clin. Cancer Res., June 15, 2008; 14(12): 3875 - 3880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Maeda, M. Oyabu, T. Yotsumoto, R. Higashi, K. Nagata, Y. Yamazoe, and I. Tamai Effect of Pregnane X Receptor Ligand on Pharmacokinetics of Substrates of Organic Cation Transporter Oct1 in Rats Drug Metab. Dispos., September 1, 2007; 35(9): 1580 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, S. Zhang, M. Sorani, and K. M. Giacomini Transport of Paraquat by Human Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Family J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 695 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-i. Asaka, T. Terada, K. Ogasawara, T. Katsura, and K.-i. Inui Characterization of the Basal Promoter Element of Human Organic Cation Transporter 2 Gene J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 684 - 689. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
